The molecular basis for cross-reacting material-positive hemophilia a due to missense mutations within the A2-domain of factor VIII

Blood

Volumn 91, Issue 2, 1998, Pages 538-548

  Amano, Kagehiro ^b   Sarkar, Rita ^b   Pemberton, Susan ^b   Kemball Cook, Geoffrey ^b   Kazazian Jr , Haig H ^b   Kaufman, Randal J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CONTROLLED STUDY; HEMOPHILIA A; HUMAN; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; STEREOSPECIFICITY;

EID: 0031972733     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.2.538     Document Type: Article

References (39)

1. Hoyer LW: The factor VIII complex structure and function. Blood 58:1, 1981
2. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30:10363, 1991
3. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ: Structure of human factor VIII. Nature 312:337, 1984
4. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM: Molecular cloning of a cDNA encoding human amihemophilic factor. Nature 312:342, 1984
5. Ortel TL, Takahashi N, Putnam FW: Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains. Proc Natl Acad Sci USA 81:4761, 1984
6. Stubbs JD, Lekntis C, Singer KL, Bui A, Yuzuki D, Srinivasan U, Parry G: cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc Natl Acad Sci USA 87:8417, 1990
7. Eaton D, Rodriguez H, Vehar GA: Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25:505, 1986
8. Lollar P, Parker ET: Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 266:12481, 1991
9. Fay PJ, Haidaris PJ, Smudzin TM: Human factor VIIIa subunit structure. J Biol Chem 266:8957, 1991
10. Hoyer LW, Breckenridge RT: Immunologic studies of antihemophilic factor (AHF, Factor VIII): Cross-reacting material in a genetic variant of hemophilia A. Blood 32:962, 1968
11. Lazarchick J, Hoyer LW: Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 62:1048, 1978
12. McGinniss MJ, Kazazian HH Jr, Hoyer LW, Bi L, Inaba H, Antonarakis SE: Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A. Genomics 15:392, 1993
13. Lollar P, Parker CG: pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 265:1688, 1990
14. Lollar P, Parker ET, Fay PJ: Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 267:23652, 1992
15. Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ: A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 79:389, 1992
16. Fay PJ, Beattie T, Huggins CF, Regan LM: Factor Villa A2 subunit residues 558 to 565 represent a factor IXa interactive site. J Biol Chem 269:20522, 1994
17. O'Brien LM, Medved LV, Fay PJ: Localization of factor IXa and factor VIII interactive site. J Biol Chem 270:27087, 1995
18. Pittman DD, Kaufman RJ: Proteolytic requirements for activation and inactivation of antihemophilic factor (Factor VIII). Proc Natl Acad Sci USA 85:2429, 1988
19. Gitschier J, Kogan S, Levinson B, Tuddenham EGD: Mutations of factor VIII cleavage sites in hemophilia A. Blood 72:1022, 1988
20. Arai M, Inaba H, Higuchi M, Antonarakis SE, Kazazian HH Jr, Fujimaki M, Hoyer LW: Direct characterization of factor VIII in plasma: Detection of a mutation altering a thrombin cleavage site (arginine-372 Æ histidine). Proc Natl Acad Sci USA 86:4277, 1989
21. Arai M, Higuchi M, Antonarakis SE, Kazazian HH Jr, Phillips JA III, Janeo RL, Hoyer LW: Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A. Blood 75:384, 1990
22. Shima M, Ware J, Yoshioka A, Fukui H, Fulcher CA: An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood 74:1612, 1989
23. Higuchi M, Wong C, Kochan L, Olek K, Aronis S, Kasper CK, Kazazian HH Jr, Antonarakis SE: Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA. Genomics 6:65, 1990
24. + haemophilia A due to a missense mutation (372 Æ Cys) at the internal heavy chain thrombin cleavage site. Br J Haematol 75:73, 1990
25. Aly AM, Higuchi M, Kasper CK, Kazazian HH Jr, Antonarakis SE, Hoyer LW: Hemophilia A due to mutations that create new N-glycosylation sites. Proc Natl Acad Sci USA 89:4933, 1992
26. Kaufman RJ: Vectors used for expression in mammalian cells, in Goeddel DV-(eds): Methods in Enzymology (vol 185). San Diego, CA, Academic Press, 1990, p 487
27. Pittman DD, Kaufman RJ: Site-directed mutagenesis and expression of coagulation factors VIII and V in mammalian cells, in Lorand L, Mann KG (eds): Methods in Enzymology (vol 222). San Diego, CA, Academic Press, 1993, p 236
28. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ: A large region (∼95kDA) of human factor VIII is dispensable for in vitro activity. Proc Natl Acad Sci USA 83:5939,1986
29. Pipe SW, Kaufman RJ: Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 271:25671,1996
30. Sanger E, Nicklen S, Coulson AR: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5463, 1977
31. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ: Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 269: 20095, 1994
32. Zatloukal K, Gotten M, Berger M, Schmidt W, Wagener E, Birnstiel ML: In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA 91:5148, 1994
33. Fay PJ, Beattie T, Regan LM, O'Brien LM, Kaufman RJ: Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: Role of subunit dissociation and factor Xa-catalyzed proteolysis. J Biol Chem 271:6027, 1996
34. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G: A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human caeruloplasmin. Blood 89:2413, 1997
35. Kemball-Cook G, Tuddenham EGD: The factor VIII mutation database on the World Wide Web: The haemophilia A mutation search test and resource site. HAMSTeRS update (Version 3,0). Nucleic Acids Res 25:128, 1997 (URL: http://europium.mrc.rpms.ac.uk)
36. Lenting PJ, Donath MJSH, van Mourik JA, Mertens K: Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 269:7150, 1996
37. 1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 271:1935, 1996
38. Lenting PJ, Christophe OD, ter Maat H, Rees DJG, Mertens K: Calcium binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain. J Biol Chem 271:25332, 1996
39. Pan Y, DeFay T, Gitschier J, Cohen FE: Proposed structure of the A domains of factor VIII by homology modeling. Nat Structure Biol 2:740, 1995